Compare · ARWR vs XCUR
ARWR vs XCUR
Side-by-side comparison of Arrowhead Pharmaceuticals Inc. (ARWR) and Exicure Inc. (XCUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARWR and XCUR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ARWR is the larger of the two at $6.25B, about 892.3x XCUR ($7.0M).
- ARWR has been more active in the news (10 items in the past 4 weeks vs 5 for XCUR).
- ARWR has more recent analyst coverage (23 ratings vs 2 for XCUR).
- Company
- Arrowhead Pharmaceuticals Inc.
- Exicure Inc.
- Price
- -
- -
- Market cap
- $6.25B
- $7.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 10
- 5
- Recent ratings
- 23
- 2
Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Exicure Inc.
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.
Latest ARWR
- SEC Form 10-K filed by Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
- Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
- Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
- Amendment: SEC Form SCHEDULE 13G/A filed by Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
- Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
- Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
Latest XCUR
- Exicure Announces Filing of Notification of Late Filing on Form 12b-25
- SEC Form DEF 14A filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
- SEC Form PRE 14A filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
- SEC Form 10-Q filed by Exicure Inc.
- Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
- Large owner Exicure Hitron Inc. acquired $2,804,738 worth of Common (623,275 units at $4.50), increasing direct ownership by 39% to 2,222,224 units (SEC Form 4)